<DOC>
	<DOC>NCT00931710</DOC>
	<brief_summary>This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).</brief_summary>
	<brief_title>Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male or female outpatient of 18 years of age or greater Stage 2 systolic hypertension defined as office Mean Sitting Systolic blood pressure (MSSBP) greater than or equal to 160 and &lt; 200 mmHg at randomization Patients who were able to participate in the study, and who gave written informed consent before any study assessment was performed. Office systolic blood pressure &gt;200 and/or mean sitting diastolic blood pressure (MSDBP) greater than or equal to 110 mmHg at Visit 1. Use of four (4) or more antihypertensive medications within 30 days of Visit 1. Refractory hypertension, defined as blood pressure &gt;140/90 mmHg while taking three (3) drugs at the maximum dose of each drug, one of which must be a diuretic. (Therapy with a fixeddose combination of two active medications represents two drugs). Inability to safely discontinue all antihypertensive medications for 12 weeks prior to randomization. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>combination therapy</keyword>
	<keyword>valsartan</keyword>
	<keyword>cardiovascular diseases</keyword>
</DOC>